Unlocking the Potential of COL1A2: A novel Drug Target and Biomarker for Fibrosis and Chronic Pain

Target Name: COL1A2

NCBI ID: G1278

COL1A2

Unlocking the Potential of COL1A2: A novel Drug Target and Biomarker for Fibrosis and Chronic Pain

Introduction

Fibrosis and chronic pain are significant public health issues that affect millions of people worldwide. The uncontrolled growth of cells in the body, known as fibrosis, can lead to the loss of tissue, while chronic pain can significantly impact a person's quality of life. Although there are several treatments available for these conditions, the search for new, more effective approaches continues to be a major focus in the medical field.

One promising candidate for new drug development is the COL1A2 protein. COL1A2 was found to be involved in a variety of physiological processes, including cell proliferation, differentiation, migration and extracellular matrix formation. COL1A2 also plays an important role in many diseases, such as inflammation, tissue damage and tumors. Therefore, studying the pharmacological effects of COL1A2 and its potential as a drug target are of great significance for the treatment of fibrous tissue and chronic pain.

Biological functions of COL1A2

COL1A2 is an important collagen protein that is expressed in a variety of tissues. Its main function is to participate in the synthesis and structure of collagen. COL1A2 is made of

Protein Name: Collagen Type I Alpha 2 Chain

Functions: Type I collagen is a member of group I collagen (fibrillar forming collagen)

The "COL1A2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about COL1A2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets